Upon completion of this podcast, participants should be able to: –Select first-line therapy for treatment-naive CLL/SLL, taking into consideration the regimen s toxicity profile, prognostic variables, comorbidities, duration, and patient preference –Plan an individual treatment approach including sequence of therapy for relapsed/refractory CLL/SLL to optimize clinical benefit and quality of life in alignment with patient preference –Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target
- Provider:National Comprehensive Cancer Network
- Activity Link: https://clinicaloptions.com
- Start Date: 2024-05-09 05:00:00
- End Date: 2024-05-09 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: BeiGene - Amount: 0.0 - Is Kind Support: False Source: Lilly (Any division) - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Community/Population Health, Learner Knowledge, Learner/Team Competence, Learner/Team Performance, Patient Health
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest